BCAX
Bicara Therapeutics Inc. Common StockNASDAQHealthcare$21.47+4.73%ClosedMarket Cap: $1.18B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.95
P/S
0.00
EV/EBITDA
-7.15
DCF Value
$1.64
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-32.0%
ROIC
-38.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-41.1M | $-37.4M | $-0.68 | — |
| FY 2025 | $0.00 | NaN% | $-155.6M | $-137.9M | $-2.52 | — |
| Q3 2025 | $0.00 | NaN% | $-40.7M | $-36.3M | $-0.67 | — |
| Q2 2025 | $0.00 | NaN% | $-32.0M | $-27.4M | $-0.50 | — |
| Q1 2025 | $0.00 | NaN% | $-41.8M | $-36.8M | $-0.68 | — |
| Q4 2024 | $0.00 | NaN% | $-26.6M | $-21.0M | $-0.38 | — |
| FY 2024 | $0.00 | NaN% | $-82.4M | $-68.0M | $-1.25 | — |
| Q3 2024 | $0.00 | NaN% | $-20.6M | $-17.5M | $-0.32 | — |
| Q2 2024 | $0.00 | NaN% | $-19.8M | $-17.0M | $-0.27 | — |
| Q1 2024 | $0.00 | NaN% | $-15.4M | $-12.5M | $-0.27 | — |
| Q4 2023 | $0.00 | NaN% | $-13.7M | $-12.4M | $-0.23 | — |
| FY 2023 | $0.00 | NaN% | $-39.9M | $-52.0M | $-1.00 | — |